ADC Therapeutics SA (ADCT) revenue breakdown
By product, Product revenues, net is the largest at 90% of fiscal 2025 revenue, growing -1% a year over 3 years.
By region, U.S. is the largest at 90% of fiscal 2025 revenue, growing -1% a year over 3 years.
Revenue by product
Fiscal years, as ADC Therapeutics SA reports them in its 10-K filings; fiscal 2025 total $81M.
| Products | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| Product revenues, net | $75M | $69M | $69M | $74M | 90% |
| License revenues | — | — | — | $5M | 6% |
| Royalties | — | $498,000 | $2M | $3M | 3% |
| License revenues | $135M | — | — | — | — |
Revenue by region
Fiscal years, as ADC Therapeutics SA reports them in its 10-K filings; fiscal 2025 total $81M.
| Regions | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| U.S. | $75M | $69M | $69M | $74M | 90% |
| EMEA | $105M | $498,000 | $2M | $8M | 10% |
| Japan | $30M | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ADCT.
Open ADCT in InvestinglyQuestions
Where does ADC Therapeutics SA make its money?
In fiscal 2025, by product: Product revenues, net $74M, License revenues $5M, Royalties $3M.
From ADC Therapeutics SA's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.